Repros Therapeutics Inc. Receives FDA Guidance for Proellex® Low Dose Oral Uterine Fibroid Clinical Program
THE WOODLANDS, Texas, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has received guidance from the FDA regarding its clinical program for low dose oral Proellex in the treatment of uterine fibroids.
Help employers find you! Check out all the jobs and post your resume.